Business
BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective on 18 August, 2025.
About this update from Preveceutical Medical Inc
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - August 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective on 18 August, 2025.","length":520,"tagName":"p"},{"type":"text","content":"Dr. Albarazanji brings a wealth of expertise in in vivo pharmacology, target validation, and translational research. Most recently, he served as a Senior Scientist in Cardiovascular & Metabolic Diseases at a leading pharmaceutical company, where he led programs on enteropeptidase inhibitors for metabolic diseases and AMPK activators for acute kidney injury. His career spans notable roles at SmithKline Beecham (now GSK), where he contributed to groundbreaking work on renin inhibitors for hypertension, insulin sensitizers like Avandia, and neuropeptide programs for obesity. Dr. Albarazanji has championed multiple novel targets, including GPR39 agonists, muscarinic M3 receptor antagonists, and vasopressin V1b antagonists, resulting in significant advancements in weight loss, glucose metabolism, and gastrointestinal hormone regulation.","length":847,"tagName":"p"},{"type":"text","content":"A prolific researcher, Dr. Albarazanji holds numerous patents and has authored over 20 peer-reviewed manuscripts in prestigious journals such as Diabetes, Journal of Pharmacology and Experimental Therapeutics, and American Journal of Physiology. His work has been presented at major conferences, including the American Diabetes Association and Keystone Symposia, and he has been instrumental in advancing compounds from discovery to clinical trials.","length":449,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Dr. Albarazanji to BioGene Therapeutics," said Stephen Van Deventer, Chairman & CEO of BioGene Therapeutics Inc. "His deep knowledge in metabolic disease biology and proven track record in leading cross-functional teams will accelerate our pipeline of innovative therapeutics. Kamal's vision aligns perfectly with our mission to addres...